header logo image


Page 760«..1020..759760761762..770780..»

The application of technology in the fields of medicines and living sciences – BPhrm Dv

January 8th, 2020 11:44 pm

There are some fascinating possibilities for using nanotechnology in medicine. Some techniques are only imagined, while others are being tested at different stages.

The nanotechnology field of medicine includes applications of currently-developed nanoparticles and longer-range work involving the use of engineered nano-robots to repair cellularly (sometimes called nanomedicine).

Regardless of what you call nanotechnology, it can revolutionize the manner in which we diagnose and treat human corporal and disease damage in the future, and many technologies only imagined a few years ago, are making significant progress towards becoming reality.

A report on the opportunities offered by nanobiotechnology was published by the German pharmaceutical group, VFA.

The report found that Germany holds a strong position with 1,100 companies in space, including nanobiotechnology, the application of technology in the fields of medicines and living sciences, in the area of nanotechnology.

The relatively young research field has the potential to further improve diagnostic and therapeutic chances for diseases which had not or can not have previously been treated sufficiently Currently used in medical and pharmaceutical nanobiotechnological methods include high-data screening to seek new targets structures and substances, alongside the use of nanotechnology

Many nano-cancer therapies as medical devices for the treatment of brain and liver tumors have also been approved since 2010. Many other nano-based life science technologies are currently being developed in different stages.

The VFA supports a rise in nanobiotechnology technical leadership, exploiting the potential of nanomedicine and actively promoting nanomedicine, believing that this is a major advantage for patients.

The still very recent field of research can further enhance the diagnostic and therapeutic prospects for previously incurable or not adequately treatable diseases, explains a concluding statement from the VFAs view of this topic.

Public discussion will continue to highlight the huge opportunities provided by nanobiotechnology and nanobiotechnology applications that patients already can gain from today, the statement says.

The overall aim must be to consider and overcome concerns about this new technology on a large societal basis.

Whatwe'vecaterpillar-trackedand seenwithin thelast four yearsmay be aspiritedscheme,thatwaswithin thepast,terriblye-commerce health-centered totoday,terriblysubtlewith AI drug discovery, clinical trials, and digitalmedicine, etc. In 2018,the wholequantityofcapitalthat wasendowedin the Asia Pacific amounted toconcerning$6.8B.To placein context,within theUSits$8.2B and $2B for Europe,aforesaidJulien de Salaberry, Chiefmilitary officer& Founder,anatomistGrowth Asia

DNA play an important part in humans and their development. DNAs are the core reason behind everything in our life. It shapes our body, functions, features and even the capability of receiving certain diseases. The core of DNAs has not

DNA play an important part in humans and their development. DNAs are the core reason behind everything in our life. It shapes our body, functions, features and even the capability of receiving certain diseases. The core of DNAs has not

Read more:
The application of technology in the fields of medicines and living sciences - BPhrm Dv

Read More...

What are the Upcoming Trends of Nanotechnology in Medicine? – Medical Tech Outlook

January 8th, 2020 11:44 pm

Nanotechnology is a rapidly expanding area of research with massive potential in many sectors ranging from healthcare to construction, and electronics.

FREMONT, CA: In the field of medicine, nanotechnology has revolutionized drug delivery, gene therapy, diagnostics, and various other areas of research, development and clinical application. Nanotechnology is a leading technology in medicine, bettering the potential of nanotechnology to target specific cells or tissues is a popular area of interest for the companies producing nanomedicines. Numerous registered clinical trials are in progress and involve nanotechnology; many of these studies are related to oncology and other therapy areas such as autoimmune diseases, anti-fungal agents and rare diseases. Playing a significant role in the transformation of medicine, identifying the trends in nanotechnology industry is essential.

Target Specification

The area of medicinal research involves attaching nanoparticles into drugs or liposomes to enhance specific localization. Different cell types have remarkable properties, and nanotechnology can be used to recognize cells of interest. This method enables associated drugs and therapeutics to reach diseased tissue while bypassing healthy cells.

Controlled Drug Release

The capability to control the discharge of a drug or therapeutic compound from its associated nanotechnology is benefitting a lot of interest from the industry. This triggered release can be gained from inside the body or from outside the body. The internal system consists of changes in the ecosystem of tumours in comparison with the surrounding tissues, while external stimuli comprise temperature change, ultrasound, or light. At present, the research efforts are dedicated to trying to understand how to release diagnostic molecules and drugs from liposomes with heat, and microbubbles using ultrasound.

Understanding Varied Patient Populations

Generally, there is a need for a better understanding of what makes patients distinctive from each other in terms of lack of ubiquitous drug efficacy. This raises a question, why nanotechnologies are not always able to improve the therapeutic output of drugs for an individual patient. Understanding the behaviour of nanomedicines when encountering different physiological characteristics of the patients and their disease states is significant.

Production of Nanomedicine

When compared to standard drug compounds, synthesizing and producing nanomedicine is primarily believed to be more complicated. In a few cases, this can limit the potential of drug manufacturers or pharmaceutical companies to deliver large quantities of nanomedicines. Not addressing the issues related to production may make the companies less interested in investing resources in this industry.

Follow this link:
What are the Upcoming Trends of Nanotechnology in Medicine? - Medical Tech Outlook

Read More...

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update – Yahoo Finance

January 8th, 2020 11:44 pm

Regulatory News:

"After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given NBTXR3s universal mode of action, our proof-of-concept in soft tissue sarcoma, and promising results from our phase I trial in head and neck cancers, we are confident that NBTXR3 activated by radiation therapy has the potential to significantly improve treatment outcomes for head and neck cancer patients. Beyond head and neck, we will continue to expand into additional indications and combination therapies. Ultimately, we aim to change the oncology treatment paradigm for millions of patients around the world." Laurent Levy, CEO of Nanobiotix

NANOBIOTIX (Euronext : NANO ISIN : FR0011341205 the Company) today announced its global development strategy for 2020 and beyond, following proof-of-concept (POC) and European market approval for NBTXR3 in locally advanced soft tissue sarcoma of the extremities and trunk wall (Brand Name: Hensify) in 2019. The Company will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology (I/O) program and evaluate NBTXR3 in other indications such as lung, pancreatic, esophageal, hepatocellular carcinoma (HCC), prostrate, and rectal cancers. To execute this plan, Nanobiotix will focus on H&N cancers while its collaborators (i.e. The University of Texas MD Anderson Cancer Center (MD Anderson) in the US and PharmaEngine in Asia) are working on other indications.

Global Development Plan Visualization

TRIAL

STATUS

ANTICIPATED NEXT STEPS

Development in Head and Neck Moving Forward

Phase III Registration Trial for NBTXR3 in head and neck patients ineligible for cisplatin

TRIAL NAME: STUDY 312

Nanobiotix trial

Design completed based on last interactions with FDA and European payers (EUnetHTA)

Jan 2020 - Submission of final protocol to FDA and other global regulatory bodies

Phase I and Phase I Expansion Trial for NBTXR3 in head and neck patients ineligible for cisplatin or intolerant to cetuximab

TRIAL NAME: Study 102/ 102 Expansion

Nanobiotix trial

Phase I dose escalation completed / data reported 19 patients

Dose Expansion 38 of 44 patients recruited

Q1 2020 - Update of dose escalation patients follow-up

Mid 2020 - First expansion phase data on efficacy and safety of dose expansion

Phase I/II Trial for NBTXR3 combined with cisplatin for head and neck patients

TRIAL NAME: PEP503-HN-1002

PharmaEngine trial

3rd dose level recruiting

H2 2020- Last patient in for 5th (last) dose level

Immuno-Oncology Program with NBTXR3

Phase I Basket Trial for NBTXR3 combined with pembrolizumab or nivolumab in H&N, lung metastasis, liver metastasis patients

TRIAL NAME: Study 1100

Nanobiotix trial

First patients treated

Protocol extended to include patients with lung and liver metastases from any primary tumor. Recruitment ongoing

Mid-year 2020 - first data reported

Phase II Trial of reirradiation with NBTXR3 combined with anti-PD-1/L1 for inoperable, locally advanced HN cancer

Phase II Trial for NBTXR3 combined with anti-PD-1 or anti-PD-L1 in Stage IV lung cancer

Phase I Trial for NBTXR3 combined with anti- CTLA4 and anti-PD-1 or PD-L1 in patients with advanced solid tumors and lung or liver mets

Phase II Trial for NBTXR3 for recurrent/metastatic HNSCC patients with limited PD-L1 expression

MD Anderson trials

Final stage of protocol development

Q2-Q3 2020 - Submission of protocols to FDA

Development Across Other Indications

Phase I Trial for NBTXR3 in hepatocellular carcinoma and liver metastasis patients

TRIAL NAME: Study 103

Nanobiotix trial

Recruitment of the last patient at the 5th (last) dose level (one patient left to be treated)

Q1 2020 - Update on results

Phase I Trial for NBTXR3 in prostate cancer patients

TRIAL NAME: Study 104

Nanobiotix trial

2nd dose level recruiting

Q4 2020 - Update on results

Phase I Trial for NBTXR3 in pancreatic cancer

Phase I Trial for NBTXR3 in lung cancer patients in need of reirradiation

Phase I Trial for NBTXR3 in esophageal cancer patients

MD Anderson trials

Pancreas Regulatory process ongoing

Lung re-irradiation / Esophageal Submission of final protocol to regulatory process

Q2 2020 - First patient treated in pancreas

Q3 2020 - Lung re-irradiation / Esophageal first patient treated

Phase I/II Trial for NBTXR3 combined with chemotherapy in rectal cancer patients

TRIAL NAME: PEP503-RC-1001

PharmaEngine trial

4th (last) dose level recruiting

H2 2020 - Report phase I results

Next Steps in Soft Tissue Sarcoma

Phase III Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: Act.In.Sarc

Nanobiotix trial

Trial completed / data reported

H2 2020- Further follow up of the patients

Post-Approval Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: TBD

Nanobiotix trial

Design established (100 patients)

H2 2020 - Trial authorization by the relevant regulatory bodies expected

Development in Head and Neck Moving Forward

There are approximately 700,000 new head and neck cancer patients worldwide each year300,000 of these patients reside in the US and the European Union (EU) 1. Of these patients at diagnosis, 90% suffer from local disease and the remaining 10% have metastatic disease. 70-80% of all Head and Neck patients will receive radiation therapy, but significant unmet medical needs remain regarding either local control, systemic control, toxicity, or some combination of the three2. This is especially challenging for patients ineligible for platinum-based chemotherapy (cisplatin).

Global Registration Trial for NBTXR3 in Head and Neck Patients Ineligible for Cisplatin

As previously announced, Nanobiotix has begun interacting with the US Food and Drug Administration (FDA) on its regulatory pathway and met with the agency in October 2019 to refine the design elements of Study 312a phase III investigators choice, dual-arm, randomized (1:1) global registration trial including elderly head and neck cancer patients who are ineligible for platinum-based chemotherapy (cisplatin).

More than half of head and neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease ordinarily requires aggressive, concerted measures. Due to potential comorbidities and toxicities associated with treatment, elderly and frail patients suffer from limited therapeutic options. Study 312 aims to target the unmet needs of this population.

Patients in the control arm will receive radiation therapy with or without cetuximab (investigators choice), and patients in the treatment arm will receive NBTXR3 activated by radiation therapy with or without cetuximab (investigators choice). The trial will recruit around 500 patients, the initial readout will be based on event-driven progression-free survival (PFS), and the final readout will be based on PFS and overall survival (OS). The study will be powered to demonstrate the OS superiority of NBTXR3 activated by radiation therapy. In addition, quality of life (QoL) will be measured as a key secondary outcome.

The Companys next step is to submit the final trial design to FDA and other global regulatory bodies within the month. A futility analysis is expected 18 months after the first patient is randomized, the interim analysis for PFS superiority is expected at 24-30 months, and final analysis will report on PFS and OS. In the event of favorable data from the initial readout, Nanobiotix plans to apply for conditional registration in the US.

Story continues

Confirming Efficacy with Phase I (Study 102) Expansion

Nanobiotix has already reported promising early signs of efficacy for patients with head and neck cancer through Study 1023 a phase I trial of NBTXR3 nanoparticles activated by intensity-modulated radiation therapy (IMRT) in the treatment of advanced-stage head and neck squamous cell carcinoma (HNSCC). The patient population for Study 102 includes elderly and frail patients who are ineligible for cisplatin or intolerant to cetuximab.

As a result of this report, the Company launched an expansion cohort with 44 additional patients to strengthen preliminary efficacy data. Recruitment for the expansion cohort has reached 38 of 44 patients and the initial readout is expected by mid-2020. Depending on the favorability of the final expansion phase data, the Company may seek to expedite the regulatory process in the EU.

Additional Development in Head and Neck with Collaborators

See more here:
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update - Yahoo Finance

Read More...

Triple Negative Breast Cancer Treatment Market Is Expected To Expand US$ 720 Mn By 2026 – Instanews247

January 8th, 2020 11:44 pm

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018. This is indicative of aCAGR of 4.7%during the period2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

See the rest here:
Triple Negative Breast Cancer Treatment Market Is Expected To Expand US$ 720 Mn By 2026 - Instanews247

Read More...

Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 – Primo…

January 8th, 2020 11:44 pm

The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Healthcare Nanotechnology (Nanomedicine) Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Healthcare Nanotechnology (Nanomedicine) Market during the forecast period 2015 2021.

As per the findings of the presented study, the Healthcare Nanotechnology (Nanomedicine) Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Healthcare Nanotechnology (Nanomedicine) in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/6370

The report segregates the Healthcare Nanotechnology (Nanomedicine) Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Healthcare Nanotechnology (Nanomedicine) Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Healthcare Nanotechnology (Nanomedicine) Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Healthcare Nanotechnology (Nanomedicine) Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/6370

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Link:
Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 - Primo...

Read More...

Wadia Hospital For Children Launched A In-House Pulverization Department, First FDA Approved In Maharashtra – Mumbai Live

January 8th, 2020 11:44 pm

First-of-its-kind in-house Pulverization Department was established at Bai Jerbai Wadia Hospital for Children which is now open for all needy patients in the city. FDA has given special permission and approval after the request from the Hospital. It was inaugurated by CEO Dr. Minnie Bodhanwala. Other dignitaries who were present on the occasion were Dr. S.S. Prabhu (Medical Director), Dr Suhas Pawar (Medical Superintendent), Dr Amjadkhan Pathan (Head Clinical Pharmacology).

Pulverization is the process of reduction of medicine dose as per the need of patients. It means to grind or crush medicines into fine particles and then dividing them into the required doses as per the requirement of the patient. This technique will be useful for non-coated tablets. In order to help paediatric patients enhance their quality of life, the hospital has come forward with a great move of opening a Pulverization Department at a minimal cost. A special nano weighing scale is used for the process of dose reduction.

Also Read:Childrens Day: Wadia Hospital Introduces India's First Therapy Park For Paediatric Patients In Hospital Premises

Dr Minnie Bodhanwala, Chief Executive Officer of the Wadia Hospitals, said,

Earlier, patients relative had to be in the queue for 2-3days, for getting the pulverized medicine (dose reduction) from outside facilities. Due to the delayed dose of medicine, many patients had prolonged hospitalization just waiting for the pulverized medicine from outside. After looking into this issue, the hospital decided to start the in house Pulverization department.

She added, Now, the FDA has given special permission and approval after the request from the hospital as the paediatric dosage is different from what is recommended to the adults. Usually, the medication dosage is dependent upon the weight of the patient and hence, the paediatric patient has very small dosages requirement. Neonatal patients unit also requires nano doses of medicine which is not available in the market. Therefore, the doctor advises reducing the dose into one- forth or one-eight part which is impossible for parents. However, this dose can be reduced by well-qualified pharmacists who can do the Pulverization in the sterile and aseptic areas. The hospital remains at the forefront of the latest technology and promises to give round-the-clock-care to the patients. We are committed to coming up with more such helpful initiatives for the benefit of the patients in the near future too.

Also Read:Nutrition Rehabilitation Centre Facility Introduced At Bai Jerbai Wadia Hospital For Children (BJWHC)

Read more:
Wadia Hospital For Children Launched A In-House Pulverization Department, First FDA Approved In Maharashtra - Mumbai Live

Read More...

Six City Honors grads in Jacobs School Class of 2023 – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

January 8th, 2020 11:43 pm

They spent their middle school and high school years with a firsthand view of the development of the burgeoning Buffalo Niagara Medical Campus, including the sparkling new downtown building that houses the Jacobs School of Medicine and Biomedical Sciences.

Now, amazingly, six graduates of City Honors School find themselves in the Class of 2023 at the Jacobs School.

These first-year students Hani Al-Jabi-Lopez, Lillian Dixon, James Ghosen, Fiona Hennig, Aleena Jafri and Joseph Nathanson are all alumni of the prestigious Buffalo school adjacent to the BNMC that routinely shows up in rankings of the best public schools in the state and even the country.

Hennig graduated from City Honors in 2012 and Dixon in 2015, while the others graduated in 2014. All six were enrolled in the International Baccalaureate Diploma Program, a program that prepares students in high school for the rigors of college.

City Honors is one of our stronger inner city schools, so its not a surprise that they are preparing students that eventually end up in medical school, says Dori R. Marshall, associate dean and director of admissions. Our hope is that we can help foster relationships with other high schools through our pipeline programs so the other Buffalo public schools also see that success with students.

The Jacobs School does not break out official statistics for the high schools its medical classes attended. However, James J. Rosso, admissions adviser in the Office of Medical Admissions, says that in the past 25 years, there have not been that many graduates of one high school in a single medical class at the Jacobs School.

The six are adjusting well, and have been impressed with the faculty and staff, and the new building that houses the medical school.

The professors and the deans really care about you doing well, and really try to help us out if were struggling, says Al-Jabi-Lopez, who earned bachelors degrees in behavioral biology and Spanish from Johns Hopkins University in 2018.

The facilities are also very impressive, adds Al-Jabi-Lopez, who plans to work in a clinical setting after residency and is also interested in academic medicine.

After graduating from Cornell University in 2016 with a bachelors degree in biology, Hennig moved to Oakland, Calif., and spent three years working and enjoying some time off before applying to medical school.

Therefore, all my fellow Centaurs (the schools mascot) were two or three grades below me in high school, she says. We knew of each other but now, being in the same medical school class, I have gotten to know each of them a little bit more.

I think it is no surprise that City Honors graduates excel in whatever they choose to pursue, she adds. I personally am very fortunate to have had many resources throughout my high school and undergraduate career, including a loving, supportive family.

The Jacobs School is also given high marks.

I really like the environment that the deans and faculty have created. I feel lucky to be in this high-tech facility, says Hennig, who has been especially impressed with the anatomy lab, which is not uncommon for current and prospective students.

After medical school, she hopes to pursue a surgical residency.

My goal is to become a surgeon specializing in gender-affirming surgeries for the LGBTQ+ community, she says. I hope to make an impact on the future of medical education and curriculum, and bring more awareness to LGBTQ+ health care wherever I end up.

Dixon, who earned bachelors degrees in molecular genetics and psychology from SUNY Fredonia in 2019, also finds the Jacobs School a nice fit.

The environment here is supportive and a lot more relaxed than other medical schools that Ive seen, she says. Its more focused on our health and happiness.

Ghosen and Nathanson have been good friends since they arrived at City Honors in fifth grade.

More than anything, City Honors prepares its students for the rigors of undergraduate life, and this in turn enables us to pursuecompetitive fields of study, Ghosen says. Many of the premedical students I met in college had never been exposed to such a large and difficult workload, and coming from City Honors, the transition wasnt as difficult.

Ghosen, who earned a bachelors degree in biology from SUNY Geneseo in 2018, enjoys the collaborative atmosphere at the Jacobs School.

The workload is definitely an adjustment from undergrad, but everybody in the class has been really great, he says. Its not cutthroat everybody kind of works together and that helps.

And he can think of nothing better than staying in his hometown after he gets his degree and completes his residency.

I definitely plan to practice in the Buffalo area, and could one day see myself teaching medical students from the Jacobs School, Ghosen says.

Thats music to Marshalls ears.

Whether they do their residency here or somewhere else, our hope is that they will come back here and make this their home because there is a physician shortage here, says Marshall, whos also an associate professor of psychiatry. We need our graduates to stay here and work.

Nathanson, who earned bachelors degrees in biological sciences and psychology from UB in 2018, appreciates the solid academic foundation that has prepared him for medical school.

I think that City Honors is second to none when it comes to preparing their students for furthering their education in an advanced setting, says Nathanson, who hopes to one day run his own medical practice. I was lucky enough to already know how to study before getting to college, and have carried some of those same techniques that I used in high school all the way to medical school.

Jafri, who earned a bachelors degree in biology from Cornell University in 2018, also likes being back in her hometown.

I chose the Jacobs School because of family and friends living in the city, because Buffalo is home, and also because this school offers a truly high-quality medical education with programs and opportunities in areas that are of interest to me, she says. The tremendous developmentof the surrounding medical complex and the many hospitals affiliated with the university were also a big plus.

They are continually making adjustments to the curriculum to improve the quality of our education and to cultivate a good environment that doesnt lead to burnout, Jafri adds.

William Kresse, principal at City Honors, says there has been an upswing in students from the school headed into STEM (science, technology, engineering and mathematics) fields over the past decade, and notes that City Honors has also expanded its intensive four-year science research program at the BNMC.

We are excited that so many of our alums are making their way to the Jacobs School, Kresse says.

More here:
Six City Honors grads in Jacobs School Class of 2023 - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Read More...

Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed – Discovery Institute

January 8th, 2020 11:43 pm

A new paper in Nature Reviews Genetics, Overcoming challenges and dogmas to understand the functions of pseudogenes, is simply incredible. It documents not only that pseudogenes have been found to have widespread function but also that under current dogma in biology, and given the technical limitations, we are failing to recognize their functions. As Seth W. Cheetham and his co-authors put it, biology suffers from demotivation into exploring pseudogene function by the a priori assumption that they are functionless where The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The abstract lays out exactly what they think:

Pseudogenes are defined as regions of the genome that contain defective copies of genes. They exist across almost all forms of life, and in mammalian genomes are annotated in similar numbers to recognized protein-coding genes. Although often presumed to lack function, growing numbers of pseudogenes are being found to play important biological roles. In consideration of their evolutionary origins and inherent limitations in genome annotation practices, we posit that pseudogenes have been classified on a scientifically unsubstantiated basis. We reflect that a broad misunderstanding of pseudogenes, perpetuated in part by the pejorative inference of the pseudogene label, has led to their frequent dismissal from functional assessment and exclusion from genomic analyses. With the advent of technologies that simplify the study of pseudogenes, we propose that an objective reassessment of these genomic elements will reveal valuable insights into genome function and evolution.

They immediately caution that there are many instances where DNA that was dismissed as pseudogene junk was later found to be functional: with a growing number of instances of pseudogene-annotated regions later found to exhibit biological function, there is an emerging risk that these regions of the genome are prematurely dismissed as pseudogenic and therefore regarded as void of function.

In 2003, Francisco Ayala and Evgeniy Balakirev wrote in Annual Review of Genetics that pseudogenes that have been suitably investigated often exhibit functional roles. This new Nature Reviews Genetics paper offers a very similar statement: Where pseudogenes have been studied directly they are often found to have quantifiable biological roles. Its a long narrative that recounts how many scientists mistakenly dismissed stretches of DNA as pseudogenes. They document dozens of instances where pseudogenes in humans and other organisms have been found to have function.

Some of these functions are protein-based, meaning the pseudogene actually generates a functional protein. But other functions can be RNA-based or DNA-based. For example, most evolutionists would presume that a pseudogene that does not produce a protein cant be functional. But the paper observes that pseudogenes that cannot be translated into a protein may still have a function through their RNA transcript:

Many pseudogenes contain a frequency of mutations that render them unlikely to be (or incapable of being) translated into proteins. However, such mutations do not necessarily preclude pseudogenes from performing a biological function.

The paper notes that even if the RNA transcript of a pseudogene cant be translated into protein, a myriad of RNA-based regulatory mechanisms have been described for pseudogenes, including processing into small interfering RNAs (siRNAs) that may regulate their parent genes, acting as a decoy for transcription factors and, most prominently, as molecular sponges for microRNAs.

Many evolutionists would forcefully assume that if a pseudogene cant even produce an RNA transcript then it cant be functional. But it turns out that pseudogenes that dont produce any RNA transcript (i.e., arent transcribed) can still have important functions:

Another mechanism through which pseudogenes can function is by influencing chromatin or genomic architecture. HBBP1, a pseudogene residing within the haemoglobin locus, enables the dynamic chromatin changes that regulate expression of fetal and adult globin genes during development. Notably, although inhibiting HBBP1 transcription has no effect, deletion of the genomic locus reactivates fetal globin expression. HBBP1 DNA contacts, but not transcription, are required for suppressing the expression of fetal globin genes in adult erythroid cells.

A variety of other non-transcriptional functions are documented in the paper, including stabilizing chromosomes, mediating transcript-splicing, and regulating recombination. Thus, in many cases copy numbers of pseudogenes seem to have functional importance, where deviations from the normal genetic state causes disease. They predict: It is expected that further links between human pseudogene polymorphisms and complex diseases will be identified in the coming years

The implication is that one reason we presume pseudogenes are functionless is because we havent been looking for their functions. And why didnt we look for their functions? Because we presumed they were functionless! So theres a circular aspect to the reasoning here. It has created the science-stopping junk-DNA paradigm, which has prevented us from understanding what pseudogenes really do.

The typical response from evolutionists would be that all of these examples of functional pseudogenes are just isolated rare cases, and that the bulk of pseudogenes are clearly junk. The authors of the paper who give no indication of sympathy for intelligent design, but definitely oppose dismissing pseudogenes as junk are aware of this objection. They say the following in direct rebuttal to it:

The examples of pseudogene function elaborated on here should not imply that pseudogene functionality is likely to be confined to isolated instances. At least 15% of pseudogenes are transcriptionally active across three phyla, many of which are proximal to conserved regulatory regions. It is estimated that at least 63 new human-specific protein-coding genes were formed by retrotransposition since the divergence from other primates. Numerous retrogenes continue to be recognized as functional protein-coding genes rather than pseudogenes across species. High-throughput mass spectrometry and ribosomal profiling approaches have identified hundreds of pseudogenes that are translated into peptides. Although the functions of these peptides remain to be experimentally determined, such examples illustrate the challenge in substantiating a genepseudogene dichotomy.

They continue: As the abundance of such [non-coding-DNA] acquired functions does not appear to be an especially rare or isolated phenomenon, it would seem remiss to take the default perspective that processed pseudogenes are functionless. Instead, it is probable that pseudogene-containing regions of the genome harbour important biological functions that are yet to be revealed.

They point out that current algorithmic and computational methods employed for differentiating pseudogenes and protein-coding genes may overestimate the proportion of the genome that is composed of pseudogenes. Why? Because the properties that are used to define many pseudogenes are also often found in normal protein-coding genes. For example:

Because of this, they argue that computational differentiation of pseudogenes from genes on a purely rule-based system is unlikely to be feasible as it will inherently conflict with many protein-coding genes. They therefore propose markedly softening claims that a stretch of DNA is a pseudogene: it may be useful to consider the annotation of pseudogenes in genomes as a prediction or a hypothesis rather than a classification.

As the authors show, the presumption that a pseudogene is functionless needs to be abandoned. But then, why are we still presuming they are functionless? There are three main reasons: (1) evolutionary thinking has presumed that pseudogenes are functionless junk, (2) terminological dogma reinforces a mindset that pseudogenic regions are intrinsically non-functional, and (3) technological limitations prevent us from discovering their function. The paper acknowledges that problem (3) stems from problem (2), but it fails to explicitly recognize that both problems (2) and (3) ultimately stem from problem (1). In fact it doesnt even identify problem (1) as a problem. Yet the whole situation traces back to bad evolutionary predictions. Lets look at these causes briefly, in reverse order:

The proximal cause that prevents us from understanding pseudogene functions are technological limitations. Because of the junk DNA paradigm, a lot of our biochemical techniques and technologies are set up only to identify standard protein-coding genes. They ignore and dismiss DNA that doesnt fit that mold. Only by updating our technology to detect functional DNA elements that dont necessarily fit the standard definition of a gene can be we begin to understand what pseudogenes really do. The paper explains that technical limitations, informed by our biases and assumptions, demotivate the study of pseudogene functions:

In addition to the demotivation into exploring pseudogene function by the apriori assumption that they are functionless, their systematic study has also been hindered by a lack of robust methodologies capable of distinguishing the biological activities of pseudogenes from the functions of the genes from which they are derived.

They compare the situation to that of long non-coding RNAs (lncRNAs), which were similarly dismissed initially as emanating from junk DNA or as transcriptional noise, largely by virtue of their definition as non-protein-coding. But as technology developed, lncRNAs are now widely recognized as functional and we regularly screen for their functions:

Following a combination of technology developments, genome-wide studies and detailed biochemical studies, lncRNAs are now routinely included in genome-wide analyses, and their functional potential as cellular regulators is widely recognized.

However, at present, the authors note, due in part to the experimental challenge of investigating their function and expression, pseudogenes are typically excluded from genome-wide functional screens and expression analyses. In other words, one of the main reasons we arent finding function for pseudogenes is because we arent looking for it. This needs to change, and they argue that it can.

For example, according to the paper, processed pseudogenes were presumed to have been rendered transcriptionally silent by the loss of cis-regulatory elements. But we now know that thousands of retrotransposed gene copies are transcribed and are often spliced into known protein-coding transcripts and up to 10,000 mouse pseudogenes have evidence of transcription. By trying to study these transcripts we can understand what they may be doing.

One complication is that pseudogene transcription shows cell-type specificity and dynamic expression meaning they may only be transcribed in particular places at particular times. This is all the more reason not to assume that lack of evidence for the function of a pseudogene is evidence that the pseudogene has no function! It very likely may be functional in a cell-type or a situation that we just havent properly investigated yet. As they put it, The use of assays ill-suited to analysis of pseudogenes has arguably stymied elucidation of their biological roles. But they are hopeful: CRISPR-based approaches, carefully applied, have the potential to revolutionize our ability to dissect the functions of pseudogenes. They conclude that its time to stop excluding pseudogenes from biochemical analyses and start using techniques that can identify their functions:

The use of a liberal definition of pseudogenes is attractive as it simplifies genomic analyses. This approach, often unknowingly to the researcher, leads to the consolidation of the pseudogene classification that is, their exclusion by convenience in functional studies. Many regions now considered to be dead genes potentially encode cis-regulatory elements, non-coding RNAs and proteins with impacts in human biology and health. Accordingly, determining the functions of putative pseudogenes warrants active pursuit by their inclusion in functional screens and analyses of genomic, transcriptomic and proteomic data. With innovations in long-read sequencing and CRISPR-based methodologies now readily accessible, the technological limitations that formerly motivated the exclusion from functional investigation are largely resolved.

Until we develop and apply these technologies to put pseudogenes to the proper test, the assumption that they are functionless junk is completely unwarranted. And its not hard to predict what the outcome will be. As Ayala and Balakirev noted, pseudogenes that have been suitably investigated often exhibit functional roles. Or as this new paper observes, Where pseudogenes have been studied directly they are often found to have quantifiable biological roles.

Technology only reflects what people want to do, and there are reasons why biologists have created hardly any technology to investigate pseudogenes: biologists presume (wrongly) that pseudogenes are nonfunctional junk. The paper argues that the terminology associated with the junk DNA paradigm discourages investigation into their function. Thus, we have terms like pseudogene which by their very nature imply that the DNA isnt a gene but something like a wannabe gene that doesnt do anything. As the authors note, the definition of a pseudogene as defective means the non-functionality of pseudogenes remains the dominant and default perception. Citing Thomas Kuhn and his concept of a dominant paradigm that is intolerant of criticisms, they lash the junk-pseudogene paradigm in strong terms:

[T]he term pseudogene itself asserts a paradigm of non-functionality through its taxonomic construction. Pseudogenes are defined as defective and not genes. This point is highlighted because impartial language in science is known to inherently restrict the neutral investigation between conflicting paradigms. In the case of pseudogenes, the term itself is constructed to support the dominant paradigm and therefore limit, consciously or unconsciously, scientific objectivity in their investigation.

Its hard to imagine a greater indictment of the idea that pseudogenes are generally functionless. They continue to explain how use of the term pseudogene hinders scientific research:

Although the pseudogene concept arose to describe an individual molecular phenomenon, the term was rapidly adopted to annotate tens of thousands of genomic regions that met only loosely defined criteria and was effectively axiomatized without being subject to any rigorous scientific debate. This lack of consensus-seeking process has left genome biology with a legacy concept that obscures objective investigation of genome function.

They recommend using different language where [t]he automated classification of gene-like sequences as pseudogenes should be avoided. Instead, we propose that descriptive terms that do not make functional inferences should be used in reference to genomic elements that arose from gene duplication and retrotransposition and terminology should not impose any unsubstantiated assumption on end users.

So what is now stopping us from elucidating the functions of pseudogenes? The only obstacle is a mental block not a technical or evidential one:

The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The paper predicts that as soon as we lose this mindset, there will remain no technical limitations blocking us from progress in understanding the functions of pseudogenes: With renewed scientific objectivity, we anticipate that a wealth of discoveries to understand genome function, its role in disease and the development of new treatments is within reach.

Thats good news, but we must ask a question the paper fails to ask: Why did this terminology develop in the first place?

Evolutionary thinking is the cause that ultimately created, nurtured, and sustained the junk DNA paradigm. Yet the paper adopts a wholly evolutionary approach, and for this reason never identifies evolutionary thinking as the root problem. The closest the authors get is when they recount how the very first paper to identify a pseudogene (published in 1977) dismissed its potential function as a relic of evolution:

In the absence of evidence that the 5S pseudogenes were transcribed, Jacq etal. concluded that the most probable explanation for the existence of the pseudogenes is that they are a relic ofevolution and are functionless1. Since the coining of the term pseudogene, its definition has broadened and is now widely accepted to define any genomic sequence that is similar to another gene and is defective.

This 1977 paper by Jacq et al. was published in the journal Cell and found a pseudogene in an African frog. That paper concluded:

We are thus forced to the conclusion that the most probable explanation for the existence of the pseudogene is that it is a relic of evolution. During the evolution of the 55 DNA of Xenopus laevis, a gene duplication occurred producing the pseudogene. Presumably the pseudogene initially functioned as a 55 gene, but then, by mutation, diverged sufficiently from the gene in its sequence so that it was no longer transcribed into an RNA product.

And there you have it: The pseudogene is seen as a mere a relic produced by mutation until it diverged so much that it was no longer transcribed into an RNA product. This is the classic view of a pseudogene.

Ironically, the 1977 paper went on to speculate that perhaps there is evidence for function for the pseudogene, but the authors privilege the relic view as the right answer until a function can be proven:

This evolutionary explanation for the presence of the pseudogene, however, is incomplete by itself in that it ignores the conservation in sequence of the pseudogene, and indeed of the entire G + C-rich spacer of 55 DNA. In an attempt to explain this, it has been suggested that the pseudogene may be a transcribed spacer corresponding to a primary transcript of 55 RNA, which is a transient precursor and has not so far been detected. If this is so, then most of the G + C-rich region of 55 DNA would be the structural gene for 5S RNA. This function, if true, would provide the necessary selective pressure to conserve the sequence of the linker and pseudogene region so that the correct processing of the postulated 300-long precursor was maintained. In the absence of any experimental evidence for such a long precursor, however, this suggestion must be regarded as speculative; it is more probable that the pseudogene is a relic of evolution.

The recent Nature Reviews Genetics paper hopes to remedy this problem by reviewing much of the overwhelming evidence for pseudogene function and emphasizing how the the non-functionality of pseudogenes remains the dominant and default perception. This will limit, consciously or unconsciously, scientific objectivity in their investigation. The authors are to be commended. However, experience teaches that unless you address the root cause of a problem, it rarely goes away. The tendency to view pseudogenes as a relic of evolution probably wont change as long as you presume that the entire genome is the product of blind evolution. The paper fully endorses the latter view, providing all kinds of narrative gloss that describes pseudogenes (whether functional or not) as retrocopies that arose from gene duplication and transposition. They emphasize:

In the fundamental reductionist approach often assumed in genetics and molecular biology, the perspective is often lost that life as we observe it today is not only the product of billions of years of evolutionary processes but also still subject to these same processes.

They are welcome to take the reductionist approach often assumed in genetics and molecular biology. But until those fundamental evolutionary views of the genome are on the table for questioning, they wont make much progress in shaking the science-stopping assumptions of the junk-DNA paradigm.

Photo: Xenopus laevis, by Brian Gratwicke [CC BY 2.0], via Wikimedia Commons.

Excerpt from:
Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed - Discovery Institute

Read More...

Scientists link mysterious snippets of DNA to cell growth and tumor suppression – GeekWire

January 8th, 2020 11:43 pm

Its been 80 million years since our our evolutionary branch diverged from mice so why do we share some fragments of DNA that are essentially unchanged? (Fred Hutch News Service Illustration / Kim Carney)

Why do some strings of genetic code remain virtually unchanged despite tens of millions of years of evolutionary divergence? A newly published study that takes advantage of the gene-editing technique known as CRISPR has found that at least some of those DNA strings are essential to keep healthy cells growing and block the growth of tumor cells.

The research, published today in Nature Genetics, is the first study finding large-scale importance of these highly conserved elements, senior author Rob Bradley of Seattles Fred Hutchinson Cancer Research Center said in a news release.

Bradley and his colleagues say unraveling the mysteries of those ultra-conserved elements could lead to new avenues for cancer treatment.

The study started out with a molecular analysis focusing on specialized snippets of DNA known as poison exons. Such snippets regulate the activity of cells by shutting off the production of particular proteins. Theyve been called kill switches for cellular functions. When they go haywire, they can cause maladies such as epilepsy. But when they work the way theyre supposed to, they can poison the production of undesirable proteins and keep cells on the right track.

Scientists have previously noticed an overlap between poison exons and ultra-conserved elements, but they puzzled over why the poison exons were so essential that theyve been relatively untouched by evolutionary pressures. In order to solve the puzzle, the Fred Hutch team made use of a CRISPR gene-editing enzyme that was modified with guide-RNA molecules to hunt down and snip out hundreds of poison exons from the DNA code in human cells.

Bradley and the studys lead author, Fred Hutch researcher James Thomas, call their technique paired guide RNAs for alternative exon removal, or pgFARM (pronounced like pig farm). Whats unique about what James did is not the approach per se, but that hes doing it in high throughput, Bradley said.

The researchers identified 465 poison exons that were highly conserved in humans, mice and rats as well as another 91 poison exons that werent so highly conserved. When they knocked out the ultra-conserved exons in cells that were grown in a lab dish, the cells died off.

As a follow-up, the team tested the role of poison exons in live mice that had lung tumors. Many of the exons were essential for normal cell growth, just as they were for the cells in the lab dish. Even more intriguingly, some of the exons had tumor-suppressing effects that were clinically relevant, the researchers reported.

Tumor-fighting poison exons tended to turn up within the genes that govern RNA splicing, a vital part of the cells protein-making machinery. Those exons may well rein in RNA-splicing factors that could otherwise promote tumor growth.

Scientists are already working on techniques to fix RNA-splicing problems that contribute to a wide variety of diseases and Thomas is hopeful that ultra-conserved poison exons could point the way to new molecular targets specific to cancer treatment.

Once you find a target, its easy to build upon the previous technology that exists for therapeutics, he said.

Update for 6:15 p.m. PT Jan. 8: Weve fine-tuned this report to describe the procedures used in the experiment more accurately. In addition to Thomas and Bradley, the authors of the Nature Genetics study, RNA Isoform Screens Uncover the Essentiality and Tumor-Suppressor Activity of Ultraconserved Poison Exons, include Jacob Polaski, Qing Feng, Emma De Neef, Emma Hoppe, Maria McSharry, Joseph Pangallo, Austin Gabel, Andrea Belleville, Jacqueline Watson, Naomi Nkinsi and Alice Berger.

See the rest here:
Scientists link mysterious snippets of DNA to cell growth and tumor suppression - GeekWire

Read More...

Sight loss research needs urgent investment – The Guardian

January 8th, 2020 11:43 pm

As leading ophthalmologists and researchers we are joining the eye research charity Fight for Sight to call for urgent action on blindness in 2020 to address the research funding gap.

We know that serious sight loss doesnt discriminate it can affect anyone at any time and it is on the increase. Science can already do so much and with the advent of new gene therapies and stem cell treatments we are so close to outcomes that were not possible a decade ago. Yet so much more needs to be done to develop new universal treatments.

The main barrier is the lack of research funding. It is unacceptable that in 2020 only 1% of UK grant funding goes to eye research, even though more than 20% of people will be affected by serious sight loss in their lifetime. Blindness can have a huge impact on peoples mental health and ability to work, increasing costs on health systems and infrastructure.

In 2019 the WHO and UN general assembly both outlined that globally more investment is needed into sight loss and research. We are calling for the new government and its partners to agree a national plan on sight loss and a research agenda that will help to ensure that eye research gets the funding it badly needs. Please join us at fightforsight.org.uk and let 2020 be the year that we accelerate progress in beating blindness.

Prof Chris Hammond Frost chair of ophthalmology, Kings College London, Prof Alan Stitt Dean of innovation and impact, Queens University Belfast, Prof Alastair Denniston Consultant ophthalmologist, Birmingham University, Prof Alison Hardcastle Professor of molecular genetics, UCL Institute of Ophthalmology, Prof Lynda Erskine Chair in developmental neurobiology, Aberdeen University, Prof Jeremy Guggenheim Director of research, Cardiff University, Prof David Steel Consultant ophthalmologist, Newcastle University, Prof Chris Inglehearn Professor of molecular ophthalmology and neuroscience, Leeds University, Prof Timothy Jackson Consultant ophthalmic surgeon, Kings College London, Prof Rachael Pearson Professor of developmental neuroscience, UCL Institute of Ophthalmology, Prof Jessica Teeling Professor of Experimental Neuroimmunology, University of Southampton, Prof Colin Willoughby Professor of ophthalmology, Ulster University

Join the debate email guardian.letters@theguardian.com

Read more Guardian letters click here to visit gu.com/letters

Do you have a photo youd like to share with Guardian readers? Click here to upload it and well publish the best submissions in the letters spread of our print edition

Go here to see the original:
Sight loss research needs urgent investment - The Guardian

Read More...

Faculty and alumni appointed to state medical boards – The South End

January 8th, 2020 11:43 pm

Michigan Gov. Gretchen Whitmer appointed a number of faculty members and alumni of the Wayne State University School of Medicine to several state boards overseeing medicine and medical licensing.

Appointments to the Michigan Board of Medicine, which works with the Department of Licensing and Regulatory Affairs to oversee the practice of medical doctors ascertaining minimal entry-level competency of medical doctors and requiring continuing medical education during licensure include:

Bryan Little, M.D., Class of 1998, is the specialist in chief of Orthopedic Surgery at the Detroit Medical Center. The governor also appointed Dr. Little to the Michigan Task Force on Physicians Assistants. That entity works with the Department of Licensing and Regulatory affairs to oversee the practice of physicians assistants. The terms of both appointments expire Dec. 31, 2023.

Angela Trepanier, M.S., CGC, professor of Molecular Medicine and Genetics and director of the Genetic Counseling Masters Program at the School of Medicine. She will represent genetic counselors during her term, which expires Dec. 31, 2023.

Donald Tynes, M.D., Class of 1995, clinical assistant professor for the School of Medicine and chief medical officer of the Benton Harbor Health Center, will serve a term through Dec. 31, 2023.

Hsin Wang, M.D., Class of 1999, was appointed to the Michigan Board of Licensed Midwifery, which works with the Department of Licensing and Regulatory Affairs to establish and implement the licensure program for the practice of midwifery in the state. Dr. Wang is an obstetrician-gynecologist with the Detroit Medical Center and the director of the Pelvic Health Program for DMC Huron Valley-Sinai Hospital. Her term runs through Dec. 31, 2023.

Melissa Mafiah, M.D., Class of 2014, was appointed to the Michigan Board of Occupational Therapists for a term that expires Dec. 31, 2023. Dr. Mafiah is a physical medicine and rehabilitation physician at W.H. Beaumont Hospital. The board works with the Department of Licensing and Regulatory Affairs to promulgate rules for licensing occupational therapists and ascertaining minimal entry level competency of occupational therapists and occupational therapy assistants.

Michael Dunn, M.D., chief of Medicine at the Henry Ford West Bloomfield Hospital and the senior staff physician for the hospitals Pulmonary and Critical Care Medicine Division, is an assistant clinical professor of Medicine for the School of Medicine. He was appointed to the Michigan Board of Respiratory Care, which oversees the licensure requirements and standards for respiratory therapists. His appointment runs through Dec. 31, 2023.

See the article here:
Faculty and alumni appointed to state medical boards - The South End

Read More...

Science Education and the Growth Mindset – Discovery Institute

January 8th, 2020 11:43 pm

Lately, Ive been very interested in learning more about teaching and learning. Ive been involved in coaching public speaking and debate for nearly a decade, and taught ESL classes off and on, and have recently come to realize that I am an educator. I had a professor in college who told us that if we were going to read one book on a subject, we might as well read tenwed learn a lot more and if we just kept going, before we knew it all ten would be finished. Well, often I dont do that, but recently Ive been raiding the Education section at several branches of the local library systemlearning about teaching reading, differentiated learning for gifted students, controversies over giving homework, and much more.

One gem I came across was Mary Cay Riccis Mindsets in the Classroom. And it clicked with my work at Discovery.

In learning about what Ricci and others call the growth mindset, I was reminded that the way to teach critical thinking in science is to have students engage with the content like scientists.

Growth mindset is an idea popularized by Stanford psychology professor Carol Dweck. She contrasts the idea of a growth mindset that we can become smarter as we work hard and our brains make new connections to the notion of a fixed mindset that we have whatever talents we were born with, or that our growth is limited. Here is a helpful video from Dweck on growth mindset, speaking for Khan Academy.

Mary Cay Riccis book takes Dwecks concept and gives teachers concrete nuts and bolts for how to teach growth mindset in the classroom.

I found her section on critical thinking striking. She notes:

Another important factor to consider about critical thinking is that it is not a simple skill (Willingham, 2008). According to Willingham (2008), critical thinking is a process that must be infused with content; it is not something that you can just check off a list once it is mastered. Why? Well, one reason is that the content being focused on and the complexity of thinking critically becomes more sophisticated over time it is always evolving. The practice component applied to the content knowledge is essential to develop learners who can apply critical thinking when they need to. Hand in hand with practice is persistence and effort, probably the two most important attributes of having a growth mindset!

If you embrace Willinghams argument that critical thinking is not a bunch of isolated skills, then you too (like me) may become annoyed by the amount of resources on the market that advertise ways to build critical thinking skills. Due in part to the way critical thinking is framed in these resources, the concept of accepting critical thinking as a process embedded in content rather than a set of skills can require a major shift in thinking.

As an aside, note her use of the word evolution to signify things becoming more complex over time! Thats not how evolutionists use the term. But never mind that. Ricci sees critical thinking as an essential component of the growth mindset it is key to practicing new learning.

When applied to the subject of science, critical thinking as defined here becomes synonymous with scientific inquiry. Critical thinking is a process that must be infused with content.the content being focused on and the complexity of thinking critically becomes more sophisticated over time And it is true that one cannot teach critical thinking skills in isolation. There must be a content area to analyze, and the critical thinking skills for one content area are not the same as critical thinking skills for another content area. In science, critical thinking is scientific inquiry observing, coming up with hypotheses, experimenting, recording data, drawing conclusions, etc.

One of the worlds foremost science publications, the journal Nature, has noted: [S]tudents gain a much deeper understanding of science when they actively grapple with questions than when they passively listen to answers.

Also in Nature, Jay Labov, senior education advisor from the U.S. National Academy of Sciences, commented that he sees active engagement as learning content not as something you memorize and regurgitate, but as raw material for making connections, drawing inferences, creating new information learning how to learn.

Teaching evolution well means educating in relevant aspects of scientific inquiry critical thinking too. This means, in short, exposing students to current scientific inquiries in the field the relevant, recent research.

This is from Denis Noble, Professor Emeritus and co-Director of Cardiovascular Physiology at Oxford University, and Fellow of the Royal Society, writing in the journal Experimental Physiology. He describes scientists as they learn and change their views in response to evidence.

The Modern Synthesis (NeoDarwinism) is a mid20th century genecentric view of evolution, based on random mutations accumulating to produce gradual change through natural selection. Any role of physiological function in influencing genetic inheritance was excluded. The organism became a mere carrier of the real objects of selection, its genes. We now know that genetic change is far from random and often not gradual. Molecular genetics and genome sequencing have deconstructed this unnecessarily restrictive view of evolution in a way that reintroduces physiological function and interactions with the environment as factors influencing the speed and nature of inherited change. Acquired characteristics can be inherited, and in a few but growing number of cases that inheritance has now been shown to be robust for many generations. The 21st century can look forward to a new synthesis that will reintegrate physiology with evolutionary biology. [Emphasis added.]

As I said earlier, the way to teach critical thinking in science is to have students engage with the content like scientists. What could be better than exposing them to current scientific debates and asking them to examine the evidence for themselves?

What would this kind of activity foster? I can easily see it planting questions in students minds that may blossom into full-fledged scientific inquiries. The leap is not great between enjoying science in high school and trying out science classes as a freshman or sophomore in college, and onward to graduating with a STEM degree and beginning a graduate program or ones first job in industry. For fostering future scientists, physicians, and engineers, inspiration and a growth mindset are the key.

Photo credit:Chetan MenariaonUnsplash.

View original post here:
Science Education and the Growth Mindset - Discovery Institute

Read More...

‘I would have had another kid’: How an imperfect gene test led to major surgeryand big regrets – The Daily Briefing

January 8th, 2020 11:43 pm

When Katy Mathes and six of her family members learned they had a mutation on a BRCA gene that significantly raised their risk of breast cancer they underwent major surgery. But years later, the genetic testing company lowered the family's odds of getting the disease, Amy Dockser Marcus reports for the Wall Street Journal.

In August 2015, Mathes decided to get a BRCA test. Mathes' mother had been diagnosed with breast cancer at 49, and four of her aunts had tested positive for the BRCA gene, and "moved quickly to get surgery," Dockser Marcus reports.

Mathes and her sister, Tricia Leigh, also had positive tests. The test results showed that Mathes had up to an 84% risk of developing breast cancer by age 70 and up to a 27% risk of developing ovarian cancer by age 70. Among the general population, the odds of developing breast or ovarian cancer are 7.3% and 0.7%, respectively, Dockser Marcus reports.

But the two women grappled over the decision of whether to get surgery: Mathes wanted another child and her sister was breastfeeding her second child.

After consulting with additional doctors, Mathes eventually decided to have her ovaries and fallopian tubes removed, the same procedure her aunts, sister, and mother underwent. In addition, Mathes and her sister had double mastectomies.

"I treated my test results like the Bible," Mathes said. "There was no questioning the report."

But years after the initial test, Myriad Genetics, the molecular diagnostics company that did Mathes' test as well as her relatives', changed its classification of the BRCA variant Mathes has from "pathogenic" to "unknown significance," a move that Myriad said is very unusual.

By this point, Mathes and six of her family members had undergone surgery based on their test results. When the sisters learned the news, Mathes said, "My brain just shut off."

Susan Manley, SVP of medical services at Myriad and a board-certified genetic counselor, said, "We know these are very difficult situations. We make these reclassifications very carefully. The science is evolving." She added that changing a classification from harmful to uncertain "is a rare event, but I understand that rare is of no consolation to the patient when it happens to them."

BRCA tests are among the most common genetic tests in existence, Dockser Marcus writes, and genetic testing guidelines have expanded who should receive BRCA tests. Major genetic testing companies such as 23andMe, Ancestry, and MyHeritage now offer the tests for BRCA1 and BRCA2 genes.

However, not every lab agrees on the specific classification of a BRCA gene variant, Dockser Marcus reports. That's in part because there are "tens of thousands of BRCA variants" and not all of them necessarily carry the same level of risk for a patient, Dockser Marcus reports.

Fergus Couch, a professor at the Mayo Clinic, said some variants "have intermediate or moderate levels of risk, not full-blown risk." For a number of those variants, labs "are making a judgment call but that is not always clear to the public," Couch said.

Stephen Chanock, a geneticist at the National Cancer Institute, said, "[G]enetics is murky." He added, "It's not so simple as 'Doctor, do I have to worry or don't I have to worry?'"

According to Melissa Cline, a researcher at the University of California Santa Cruz Genomics Institute, and project manager of the BRCA Exchange, the analysis on the BRCA variant in the Mathes' family put a lot of weight on a 2011 paper that found the variant likely alters the BRCA2 protein, which can help suppress tumors.

Seth Marcus, a genetic counselor at Advocate Health Care who counseled Mathes' mother and one of her aunts, said he checked a public database to see how other labs classify the variant once he heard of Myriad's change. He said six labs still classify the variant as "likely pathogenic."

"In the end, you give the patient the data and the knowledge you know," he said.

Dockser Marcus reports that Myriad currently has 38 people in its database with the BRCA variant Mathes and her relatives have, 12 of whom come from Mathes' family. Mathes said that if she had known about the sample size, she and her husband may have asked more questions about whether surgery was appropriate.

Now, based on Mathes' family history and Myriad's classification change, Mathes' genetic counselor estimated her lifetime risk of developing breast cancer is 21%, Dockser Marcus writes.

"That is not high enough to make me remove organs," Mathes said. "I would have had another kid. I would have waited to do surgery" (Dockser Marcus, Wall Street Journal, 12/20/19).

Continue reading here:
'I would have had another kid': How an imperfect gene test led to major surgeryand big regrets - The Daily Briefing

Read More...

Genes explain why anxiety and depression go hand-in-hand – Futurity: Research News

January 8th, 2020 11:43 pm

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A massive genome-wide analysis of approximately 200,000 military veterans has identified six genetic variants linked to anxiety.

Some of the variants associated with anxiety had previously been implicated as risk factors for bipolar disorder, post-traumatic stress disorder, and schizophrenia.

The new study further contributes the first convincing molecular explanation for why anxiety and depression often coexist.

There has been no explanation for the comorbidity of anxiety and depression and other mental health disorders, but here we have found specific, shared genetic risks.

This is the richest set of results for the genetic basis of anxiety to date, says co-lead author Joel Gelernter, a professor of psychiatry, of genetics, and of neuroscience at Yale University.

There has been no explanation for the comorbidity of anxiety and depression and other mental health disorders, but here we have found specific, shared genetic risks.

Finding the genetic underpinnings of mental health disorders is the primary goal of the Million Veteran Program, a compilation of health and genetic data on US military veterans run by the US Veterans Administration. The research team analyzed the programs data and zeroed in on six variants linked to anxiety. Researchers found five in European Americans and one only in African Americans.

While there have been many studies on the genetic basis of depression, far fewer have looked for variants linked to anxiety, disorders of which afflict as many as 1 in 10 Americans, says senior author Murray Stein, San Diego VA staff psychiatrist and professor of psychiatry and of family medicine and public health at the University of California, San Diego.

Researchers found some variants linked to genes that help govern gene activity or, intriguingly, to a gene involved in the functioning of receptors for the sex hormone estrogen. While this finding might help explain why women are more than twice as likely as men to suffer from anxiety disorders, researchers stressed that they identified the variant affecting estrogen receptors in a veteran cohort made up mostly of men, and that further investigation is necessary.

Another of the newly discovered anxiety gene variants, MAD1L1, whose function researchers dont fully understand, was also highly notable. Variants of this gene have already been linked to bipolar disorder, post-traumatic stress disorder, and schizophrenia.

One of the goals of this research is to find important risk genes that are associated with risk for many psychiatric and behavioral traits for which we dont have a good explanation, says co-lead author Daniel Levey, a postdoctoral associate.

This is a rich vein we have just begun to tap, says Gelernter.

The research appears in the American Journal of Psychiatry.

Additional researchers from the Veteran Affairs Connecticut Healthcare System; VA San Diego Healthcare System; and the University of California, San Diego contributed to the work.

Source: Yale University

See the article here:
Genes explain why anxiety and depression go hand-in-hand - Futurity: Research News

Read More...

The Importance of Small Non-Coding RNAs in Human Reproduction: A Revie | TACG – Dove Medical Press

January 8th, 2020 11:43 pm

Behnam Kamalidehghan,1,* Mohsen Habibi,2,* Sara S Afjeh,1 Maryam Shoai,3 Saeideh Alidoost,4 Rouzbeh Almasi Ghale,4 Nahal Eshghifar,5 Farkhondeh Pouresmaeili1,6

1Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Central Laboratory, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; 4Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; 5Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran and Mens Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 6Mens Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*These authors contributed equally to this work

Correspondence: Farkhondeh PouresmaeiliMens Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranTel/Fax +98 21-23872572Email pouresfar@gmail.com

Background: MicroRNAs (miRNA) play a key role in the regulation of gene expression through the translational suppression and control of post-transcriptional modifications.Aim: Previous studies demonstrated that miRNAs conduct the pathways involved in human reproduction including maintenance of primordial germ cells (PGCs), spermatogenesis, oocyte maturation, folliculogenesis and corpus luteum function. The association of miRNA expression with infertility, polycystic ovary syndrome (PCOS), premature ovarian failure (POF), and repeated implantation failure (RIF) was previously revealed. Furthermore, there are evidences of the importance of miRNAs in embryonic development and implantation. Piwi-interacting RNAs (piRNAs) and miRNAs play an important role in the post-transcriptional regulatory processes of germ cells. Indeed, the investigation of small RNAs including miRNAs and piRNAs increase our understanding of the mechanisms involved in fertility. In this review, the current knowledge of microRNAs in embryogenesis and fertility is discussed.Conclusion: Further research is necessary to provide new insights into the application of small RNAs in the diagnosis and therapeutic approaches to infertility.

Keywords: miRNA, female fertility, male fertility, piwi-interacting RNAs, piRNAs

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
The Importance of Small Non-Coding RNAs in Human Reproduction: A Revie | TACG - Dove Medical Press

Read More...

Coral reef resilience – Penn: Office of University Communications

January 8th, 2020 11:43 pm

Mass coral-bleaching events, which occur when high ocean temperatures cause coral to expel the algae that dwell inside them, are a relatively recent phenomenon. The first widespread bleaching event occurred in 1983, the year before Penn marine biologist Katie Barott was born.

The next one happened about 15 years later. And the intervals between them continue to shrink. In 2014, one bleaching event in Hawaii was so extreme that it carried over to affect corals into a second summer.

Theyre increasing in frequency, getting closer and closer, says Barott, an assistant professor in the School of Arts and Sciences Department of Biology. And the ocean temperature is getting warmer and warmer, so the severity is increasing, too.

Yet as dramatic as the phenomenon soundsand appearscoral bleaching does not always equate with coral death. Algae can return to corals once ocean temperatures cool, and scientists have observed formerly white corals regain their color in subsequent seasons.

In a multifaceted research project funded by a grant from the National Science Foundation (NSF), Barott and members of her lab are studying the mechanisms by which corals withstand the effects of climate change, which include not only the warmer temperatures that trigger bleaching but also acidification of ocean waters, a slower-moving creep with subtle yet significant consequences.

Barotts work, based in Kaneohe Bay on Oahu, Hawaii, focuses on two of the bays dominant coral species: rice coral (Montipora capitata) and finger coral (Porites compressa). Barott began working there during a postdoctoral fellowship at the Hawaii Institute of Marine Biology, conducting studies on which the new work is based.

Corals are invertebrate animals that live in large colonies, together forming intricate skeletons of varied shapes. To obtain food, they rely heavily on a symbiotic relationship with algae, which establish themselves within the corals tissue and produce food and energy for the coral through photosynthesis. A change in temperature or pH can upset this partnership, triggering the algaes expulsion.

That leaves the coral essentially starving, Barott says.

Since her postdoctoral days, Barott has been working with colleagues in Hawaii to monitor coral patches. After the 2014-15 bleaching event, researchers were surprised and heartened to find certain patches of corals didnt succumb to the bleaching, even those located directly adjacent to stark white corals. And many of those that did bleach bounced back within a month or so of the onset of cooling autumn temperatures.

At the time Barott was writing her NSF grant application, she planned to compare the differences between bleached and unbleached corals. Yet just as the grant kicked off in July, another bleaching event was unfolding in Hawaii.

That gave us this unexpected opportunity to go back to those same colonies to see if the ones that bleached last time were the same ones that bleached again this past fall, she says. And more or less we saw the same patterns: The ones that bleached last time bleached again this time and vice versa. That gives us compelling evidence that theres something specific about these resilient individuals that is make them resist bleaching, even in very warm temperatures.

While high temperatures triggers bleaching, acidity plays a key role in coral vitality as well. Lower seawater pH impedes corals ability to build their calcium carbonite skeletons, resulting in weaker, more fragile structures.

In earlier work, Barott had discovered that corals possess a pH sensor that can respond to changes in their environment. And, indeed, sea water acidity can vary widely in the course of a day, a season, or a year, swinging as much as 0.75 pH units in a day. Perhaps, Barott hypothesizes, coral have molecular tools that they use to withstand these daily fluctuations that they could also employ to contend with the gradual ocean acidification that is occurring as the concentration of CO2 in sea water rises.

Maybe there are some reefs that are going to be more resistant to ocean acidification because theyre used to seeing these really large daily swings and are sort of primed to deal with that challenge, she says.

Shes also curious about how bleaching impacts corals ability to tolerate pH changes more generally. Using molecular tools, she and her students are investigating the epigenetic changes that affect how genes are read and translated into functional proteins in the organisms. Such changes could occur much more rapidly than coral, a long-lived species, could evolve to deal with a changing environment.

In a variety of projects, the scientists are examining differences between species of coral, between species of the algal symbionts, and between populations located in different places in the Kaneohe lagoon.

Early results suggest differences between the rice and finger coral in their strategies for managing bleaching.

One really resists the bleaching, but if it does succumb then it fares a lot worse than the one that bleaches more readily, says Barott. That one seems to be more susceptible to losing its symbionts, but if it does it recovers fast and has lower overall mortality.

Barotts group is collaborating with others in Hawaii to see if hardier corals could be propagated to rebuild damaged reef communities.

Were at the proof-of-principle stage, she says, where were trying to figure out if some of these differences are heritable.

While some of that work is being completed in Hawaii, carefully tended tanks in the basement of the Leidy Laboratories of Biology allow Barott and her students to complete experiments in Philadelphia on corals. Using both corals shipped from the field and sea anemones, a useful stand-in for corals due to their ease of care and rapid reproduction, the lab has been tracking the impacts of temperature and pH stress on energy systems, genetics, and even the microbiome of corals, the bacteria with which the corals and algae cohabitate.

The surface of coral is analogous to the lining of your lungs or intestines, Barott says. Its covered in cilia, its got a mucus layer over the top of it, and there are tons and tons of bacteria that live in that mucus layer. We think those bacteria are playing a role in the health of the coral, but we dont know if its playing a role in their temperature sensitivity, so thats something well be looking at.

With this whole organism approach, Barotts aims to inject some optimism and scientific rigor into what is a largely dire outlook for corals worldwide. Encouragingly, she notes, this years bleaching event in Hawaii was much less severe than predicted, and corals that had bleached in 2014 were less strongly affected by this years event.

These reefs are facing a lot of impacts, not just from climate but also from local development, sedimentation, nutrient pollution, she says. Our hope is to predict how corals will respond to these challenges and maybe one day use our findings to assist them in rebuilding resilient reefs.

Katie Barott is an assistant professor in the University of Pennsylvania School of Arts and Sciences Department of Biology.

Much of the work described above is funded by the National Science Foundation (Grant 1923743).

Link:
Coral reef resilience - Penn: Office of University Communications

Read More...

Durham: Hyperyields on the horizon — the competition and innovation of it all – AGDAILY

January 8th, 2020 11:43 pm

The new year new decade is afoot. What are you hoping to do better moving forward?

Usually its a self-help extravaganza. Hit the gym and shed a few pounds? Or maybe fix certain behavioral traits, with a philanthropic tie-in. Swear jars anyone?

Unfortunately, as January gym goers know, the most well-intentioned resolutions often fall by the wayside tempered by the crushing weight of existence!

No doubt, honoring resolutions is a challenge. But theres one resolute contingent of farmers that not only aspire, but deliver yearly. These are royalty, a select group of hyperyielders that squeeze every last bit of productivity out of their crops.

Appropriately named with a predictable focus on a certain ubiquitous crop the National Corn Yield Contest is organized by the National Corn Growers Association.

The reigning king is David Hula of Charles City, Virginia. In a carnival-like atmosphere often dubbed the corn wars, the Hula dynasty is unmatched.

His irrigated yield of 616 bushels per acre (bu/acre) this isnt a typo in an industry that averages 175 bushels per acre (from a diminutive 25 bu/acre in 1910) is jaw-dropping. Even more astonishing is the venue: a farm outside the Corn Belt, lacking the rich prairie soils ordinarily well-suited to the challenge.

But whats the point of this yield obsession? Is it all just chest pounding posturing by farmers seeking alpha status among their peers?

Bragging rights plays a part. But it runs beyond pride.

As expected, competition spurs and diffuses innovation. Consider the space race (OK, maybe not so friendly) between the U.S. and the former USSR, the first in flight race, or the pursuit of the land speed record. One-upmanship fuels advancement.

On occasion, it also shatters records long held as unbreakable. Consider Olympian Bob Beamons leap of the century in 1968 a feat that rewrote the record books. After breaking the previous long jump record by nearly 22 inches initially beyond the limits of the measuring equipment on hand he broke down after realizing the enormity of his accomplishment.

Similarly, Hulas 2019 entry decimated the previous corn yield record of 542 bu/acre, and set a new aspirational benchmark for productivity.

Its also instructive on another level. Despite a cavalcade of improvements, from hybrid seeds, to high density spacing, to uniform germination, to nutrition, to ag protectants, to biotech applications, were still not fully utilizing the genetic potential embedded in the humble corn seed.

But surely, were reaching a point of diminishing returns. That yield curve is going to flatten. Yet theres no evidence were even remotely close to a plateau. Indeed, Hula thinks we can attain yields of 800 to 850 bu/acre out of the bag. Its just a matter of providing the proper regimen to maximize genetic potential. A blessed union of nature and nurture.

So agronomy how the plant is tended to in the field plays a critical role in squeezing out more yield. But is nature increasingly going to be the dominant factor? As we strive toward topping out yields, its increasingly mission critical need to decipher an old enigma genetics.

That complexity has historically discouraged researchers from searching for the silver bullet a gene solely responsible for yield. Large investment, minimal success. So weve stuck with simpler applications, like transgenic (GMO) herbicide tolerance (Roundup Ready) and/or Bt proteins (built in insecticides). These arent necessarily yield-boosting on the surface. In the absence of pests and weeds, they can actually cause a yield depression. But we dont grow corn in a pest-free vacuum. In the real-world, these GMO applications do at least maintain potential yield when plants are under pressure.

Despite past challenges,a team of researchers recently identified a single gene responsible for up to 10 percent boosts in corn yield, largely independent of growing conditions. All they needed to do was tack on a new promoter, a central switch box of sorts that acts like on/off switch and volume control. Turn on that boombox 24/7, max out the volume, and plant physiology kicks in. The leaves grow larger and photosynthesize, translating to better field performance. Its like enabling a cheat code for growth.

Though the promoter and gene are already found in corn, the method used to join them together falls under the traditional definition of a GMO so expect unjustified regulatory hurdles at every turn.

Most assuredly, the next frontier in research (that will invigorate the hyperyielders of the future) is at the molecular level, paired with field optimization. Unprecedented gains are in the cards, if the neo-luddities dont evangelize a bygone past and stifle the gears of progress.

While the 10th Commandment says thou shalt not covet, everyone should be shamelessly envious. With more mouths to feed, we need to address the existential threat of food security, population growth, and environmental stewardship. David Hula and company model an algorithm that we should all emulate; the proof is in the harvest.

Tim Durhams family operates Deer Run Farm a truck (vegetable) farm on Long Island, New York. As a columnist and agvocate, he counters heated rhetoric with sensible facts. Tim has a degree in plant medicine and is an Associate Professor at Ferrum College in Virginia.

Go here to see the original:
Durham: Hyperyields on the horizon -- the competition and innovation of it all - AGDAILY

Read More...

2020 Emerging Gene Therapies Market- Trends within the Technological, Clinical, Regulatory and Competitive Landscape to 2022 – Instanews247

January 8th, 2020 11:43 pm

The Emerging Gene Therapies Market Report explores how emerging gene editing products will compete with established products, their relative competitive strengths, and upcoming value inflection points within the field.

Latest Research Report updated on ReportsnReports is Emerging Gene Therapies Market provides a comprehensive overview of the emerging gene therapy market. The report discusses gene therapy and the technology behind gene editing, outlining the advantages, limitations and current evidence for the platforms under development. The report discusses relevant clinical studies targeting specific therapeutic indications and highlights examples of current challenges within the field, with a focus on therapies that target the eye, liver, and blood.

Download FREE PDF sample of this Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1854862

Top Company Analysis in Gene Editing Market Report:

and more

Scope of the Report: What are the key emerging products within the gene therapy landscape? Which companies have the strongest pipeline of innovative products? How will gene editing disrupt existing gene therapy products? What are the regulatory trends for emerging gene therapies? What are the interests of pharmaceutical companies within the field?

Get FLAT 15% Discount on this Report @ https://www.reportsnreports.com/contacts/discount.aspx?name=1854862

Reasons to buy this Report: Achieve an up-to-date understanding of the area, with a comprehensive reference of key products within the gene therapy landscape, compared across technology-specific relevant characteristics such as editing mechanism and delivery vector. Conduct competitive analysis using indication-specific, side-by-side comparisons of the latest data for key gene therapy products in the strategically relevant areas of eye, blood, and liver. Conduct strategic analysis using an overview of gene therapy specific considerations for evaluating and developing gene therapy products the CRISPR patent space, emerging regulatory trends, innovation leaders and the interests of pharma in gene therapy.

Table of Contents in this Report:1.1 List of Tables 71.2 List of Figures 82 Introduction 102.1 Gene Therapy Definitions 102.2 Report Coverage the Emerging Gene Therapy Pipeline 112.3 History of Gene Therapy 122.4 Limitations of Gene Transfer 132.5 The Development of Targeted Gene Editing 132.6 Overview of Gene Editing Platforms 132.6.1 Zinc Fingers (1996) 132.6.2 Transcription Activator-Like Effectors (2011) 142.6.3 The CRISPR/Cas System (2013) 152.6.4 Effectors for Targeting Domains 192.6.5 Comparison of Gene Editing Systems 192.6.6 Summary of Gene Editing Systems 192.7 Overview of In Vivo Gene Therapy 212.7.1 Editing is Dependent on Cell Type, Stage, and Repair Pathway 212.7.2 Delivery 212.7.3 Emerging Safety Concerns with Editing Platforms 242.7.4 Editing Products are Reliant on the Target Cells Cycle Stage and DNA Repair Machinery 272.7.5 Advantages of Gene Editing over Gene Transfer 282.7.6 Integration into Safe Harbor Sites 282.7.7 The Increasing Complexity of Gene Therapy 302.7.8 Summary of In Vivo Gene Therapy 313 Gene Therapy Near Term Product Pipeline 333.1 Leber Congenital Amaurosis 333.1.1 Unmet Need 333.1.2 Molecular Genetics 333.1.3 Luxturna (Voretigene neparvovec) 333.1.4 Editas Medicine: EDIT-101 353.1.5 Trial Design 363.1.6 EDIT-101 and Off-Target Effects 373.1.7 The Potential Advantage of EDIT-101 is the Longevity of its Therapeutic Effect 373.1.8 Summary LCA 383.2 Choroideremia 383.3 Hurler Syndrome (MPS I) 393.3.1 Key Clinical Studies 403.3.2 Regenex: RGX-111 403.3.3 Sangamo Therapeutics: SB-318 403.4 Hunter Syndrome (MPS II) 413.4.1 Unmet Need 413.4.2 Sangamo Therapeutics: SB-913 413.4.3 Immusoft Corporation: Cell Therapy 433.5 Sanfilippo Syndrome (MPS III) 433.5.1 Lysogene: LYS-SAF302 433.6 Summary MPS Disorders 443.7 Hemophilia 443.7.1 Hemophilia A 463.7.2 Summary Hemophilia A 503.7.3 Hemophilia B 513.7.4 Summary Hemophilia B 533.8 Hemoglobinopathies 543.8.1 Beta Thalassemia: Unmet Need 543.8.2 Beta Thalassemia: Molecular Genetics 553.8.3 Sickle Cell Disease: Unmet Need 563.8.4 Sickle Cell Disease: Molecular Genetics 563.9 Cellular Therapies for Hemoglobinopathies 573.9.1 Blue Bird Bio: BB-305 (LentiGlobin) 573.9.2 Sangamo: ST-400 603.9.3 CRISPR Therapeutics: CTX-001 613.9.4 Summary: Cellular Therapies for Hemoglobinopathies 623.10 Duchenne Muscular Dystrophy 633.10.1 Unmet Need 633.10.2 Molecular Genetics 633.10.3 ExonDys 51 Sarepta Therapeutics 643.10.4 Solid BioSciences: SGT-001 663.10.5 Exonics Therapeutics: CRISPR Approach 673.10.6 Summary Duchenne Muscular Dystrophy 684 Competitive Landscape 694.1 Regulatory Considerations for Developing Gene Therapy Products 694.1.1 Product Characteristics 694.1.2 Clinical Study Design for Gene Therapy Products 694.1.3 Disease specific guidance 704.1.4 Reimbursement and Payment 714.1.5 Summary Regulatory Considerations 724.2 Intellectual Property CRISPR/Cas 724.2.1 Licensing, Exploitation, and MPEG Pool 744.3 Company Analysis: Gene Editing Companies 754.3.1 Sangamo Therapeutics 754.3.2 CRISPR Therapeutics 794.3.3 Casebia Therapeutics 814.3.4 Editas Medicine 824.3.5 Intellia Therapeutics 844.3.6 Homology Medicines 864.4 Company Analysis: Pharma 874.4.1 Amgen 874.4.2 Gilead Sciences 874.4.3 Novartis 874.4.4 Sanofi 884.4.5 GlaxoSmithKline 884.4.6 Pfizer 885 Appendix 895.1 References 895.2 Report Methodology 98

and more

See the article here:
2020 Emerging Gene Therapies Market- Trends within the Technological, Clinical, Regulatory and Competitive Landscape to 2022 - Instanews247

Read More...

BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week – GlobeNewswire

January 7th, 2020 12:54 pm

NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview at the 2020 Biotech Showcase, being held on January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

Mr. Lebovits will also present at the 3rd Annual Neuroscience Innovation Forum, taking place on January 12, 2020, at the Marines Memorial Club in San Francisco. Additionally, Ralph Kern M.D., MHSc, BrainStorms Chief Operating Officer and Chief Medical Officer, will participate on aRare & Orphan Diseases Panel.

Meetings

BrainStorms senior management will also be hosting institutional investor and partnering meetings at the 2020 Biotech Showcase conference (https://goo.gl/SGFm62). Please use the Investor contact information provided below to schedule a meeting.

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at http://www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

More:
BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - GlobeNewswire

Read More...

How These Practitioners Can Help with New Year, New You Goals – Milwaukee Magazine

January 7th, 2020 12:52 pm

The start of a new year is the perfect time to prioritize self-care and set health and wellness goals, so make 2020 your happiest yet with a new, enhanced version of you. Use this guide to find the doctors, therapists and practitioners that can help you look and feel your best.

When diet and exercise just wont provide the results youre looking for, visit Skiin Anti-Aging Lounge. They offer the only procedure that builds muscle. EMSCULPT has been proven safe and effective by the most reputable scientific methods. The procedure induces strong muscle contractions with Hifem (high-intensity electromagnetic) technology not achievable through voluntary contractions. This builds muscle and creates a sculpted, toned physique. Other services like CoolSculpting and Exilis also help clients reshape their bodies through nonsurgical, noninvasive methods. Skiin is the first and only CoolSculpting advanced education center in the nation. Another first: Exilis is the first and only device to combine radio frequency and ultrasound to tighten skin through heating and cooling.

Your face is the first place to show signs of aging, but there is a way to take back those years. Dr. John Yousif has received several awards for his research in facial aging. He has been practicing plastic and cosmetic surgery for over 30 years and has even pioneered new techniques like the Gortex Midface Lift and the Hyoid Suspension Neck Lift. At both Sier Medi-Spa and Ascension in Mequon, he offers surgical and nonsurgical procedures to reverse the signs of aging. All of the types of facelifts offered are long-lasting and natural looking, leaving clients feeling like a younger version of themselves.

RELATED The Homebody's Guide to Winter in Milwaukee

Aqua, under the direction of Dr. Christopher Hussussian, is a full-service salon, spa and med spa offering a wide range of services in a luxurious setting on Pewaukee Lake. Whether you are hoping to change the way you look or feel or both Aqua has a solution to enhance your skin and hair for both body and face. New services for the new year include hair restoration for both men and women using PRP (platelet-rich plasma) with biotin and a new weight-loss program using the HCG hormone. They also offer advanced laser hair removal, Clear Lift skin tightening, ThermiVa and CoolSculpting, a popular nonsurgical fat cell reduction with lasting results. A consultation can help you decide what services would work best to achieve a healthier, happier version of yourself.

Serving the Lake Country area, Dr. Tom Stamas is helping people put their best face forward, one smile at a time. He specializes in smile design, a full dental restoration and reconstruction for those suffering from tooth damage or loss, or for those looking to fix crooked, worn or yellowed teeth. During your personalized consultation, Stamas and his team will help you select which treatments will bring your smile to life. Dental treatments like bridges, dental implants, crowns and state-of-the-art diagnostic tools are all available to restore the health, function and appearance of your smile. Youll feel good about the natural-looking results, and your self-esteem will get a boost too.

What if you could use undesired fat from your belly to get rid of the bags under your eyes? Sounds too good to be true, right? Anew Skin and Wellness has a procedure that is done right in the office with long lasting results. The nano-fat transfer removes a small amount of fat with micro liposuction. That fat is harvested for re-injection to the appropriate areas of the face, neck, earlobes, hands and thighs. It can also be used to plump thin lips, smooth cellulite and scars and restore skin elasticity. The nano-fat transfer is safe, effective, economical and helps clients look their best. The in-office procedure provides long-lasting results because the bodys stem cells can turn the aging skin into new, rejuvenated skin. Its the natural way to tighten and smooth skin, allowing you to turn back the clock without a surgical face- or neck-lift.

RELATED Your Guide to the New and Improved Wauwatosa Village

Dr. Arvind Ahuja has provided neurosurgical and endovascular care in southeastern Wisconsin for more than 20 years for brain, spine, artery and peripheral nerve conditions. Whether patients come to Neurosurgery and Endovascular Associates for neck and/or arm pain, back and/or leg pain or headache, the first step is always diagnostic testing to determine the cause of the pain, rather than just treating the symptoms. Often through treatments like medication, steroid injections, physical therapies and if need be surgery, patients achieve improved functioning and long-term relief. Ahujas specialized training in the nervous system is incredibly effective in treating spinal conditions, and his treatments give patients the opportunity to live a happier and morefunctional life.

Read more:
How These Practitioners Can Help with New Year, New You Goals - Milwaukee Magazine

Read More...

Page 760«..1020..759760761762..770780..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick